Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsSolid TumorsProtocol groupAggressive LymphomasNeuro-OncologyDiseaseMalignant MeningitisNHL, B-Cell Type, Diffuse Large CellPrimary Lymphoma of the CNSSubgroupICD10C79.3C83.-C83.3C85.9MeSHLymphoma, Large B-Cell, DiffuseMeningeal CarcinomatosisSequenceChemotherapyChemo-substanceRituximabChemo-substanceRituximabChemo-substanceRituximabChemo-substanceRituximabNo. Substances1 RadiotherapySupportive therapySupportive substanceDimetindenFamotidineParacetamolSupportive substanceDimetindenFamotidineParacetamolSupportive substanceDimetindenFamotidineParacetamolSupportive substanceDimetindenFamotidineParacetamolNo. Substances3Protocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationseveral possibleTherapy phaseTherapy intentionpalliativeRisksEmetogenicity only studiesPublicationAuthorRubenstein JDiseaseWiederkehrendes oder refraktäres ZNS Lymphom primär oder NHL, CD20+, PS über 50OriginDivision of Hematology Oncology, University of California; Memorial Sloan-Kettering Cancer Center, New YorkProtocols in Revision 1 protocol foundProtocols under revision.Rituximab 25, Malignant Meningitis (PID2571 V1.0)
